Cautionary Statements Regarding Forward-looking Statements This presentation is provided by Ping An Healthcare and Technology Company Limited (hereinafter referred to as the "Company"). To the extent any statements made in this report contain information that is not historical, these statements are essentially forward-looking. These forward-looking statements include but are not limited to projections, targets, estimates and business plans that the Company expects or anticipates will or may occur in the fut ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1833） 截至2025年12月31日止年度的經審計全年業績公告 平安健康醫療科技有限公司（「本公司」）董事會（「董事會」）欣然公佈本公司及其 附屬公司（「本集團」）截至2025年12月31日止年度經審計全年業績公告。本公告 刊載本公司2025年度報告（「年度報告」）全文，並符合香港聯合交易所有限公司 （「聯交所」）證券上市規則中有關年度業績初步公告附載的資料之要求。 本公司審計及風險管理委員會已審閱本集團截至2025年12月31日止之年度業績。 本公告將於聯交所網站www.hkexnews.hk及本公司網站www.pagd.net發佈。年度 報告將適時於上述聯交所及本公司網站發佈並送交予本公司股東。 承董事會命 平安健康醫療科技有限 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1833） 更換董事會秘書、公司秘書及授權代表 臧珞琦女士，45歲，自2022年3月加入本公司，現任本公司執行董事、執行副總 裁兼首席財務官。臧女士目前出任本公司子公司康鍵信息技術（深圳）有限公司的 董事兼總經理。臧女士擁有豐富的全球跨國企業與中國互聯網公司財務與經營管 理、企業風險控制、融資和投資併購管理經驗，曾任職海內外普華永道、德勤會 計師事務所，及洲際酒店集團、曹操出行和滴滴出行並擔任公司與財務高管職務。 臧女士，香港公司治理公會和英國特許公司治理公會資深會士，CGMA全球特許 管理會計師，CIMA資深會員，CPA Australia資深會員，IPA公共會計師協會資深 會員，取得復旦大學文學學士學位、墨爾本大學工商管理碩士學位 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1833） 持續關連交易 2026年服務購買協議 緒言 本公司的全資附屬公司康鍵已於2026年3月24日與平安訂立2026年服務購買協 議，期限自2026年3月24日起至2026年12月31日止。 上市規則之涵義 於本公告日期，平安為本公司的控股股東，持有本公司全部已發行股本約 53.71%，因此平安為本公司的關連人士。因此，根據上市規則第十四A章， 2026年服務購買協議及其項下擬進行交易構成本公司的持續關連交易。 由於2026年服務購買協議的年度上限的最高適用百分比率超過0.1%但低於5%， 故2026年服務購買協議及其項下擬進行的交易須遵守上市規則第十四A章下的 申報、公告及年度審閱規定，但獲豁免遵守獨立股東批准的規定。 緒言 本 ...

（股份代號：1833） PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 郭曉濤先生 主席 中國，上海 二零二六年三月二日 於本通告日期，董事會由執行董事何明科先生及臧珞琦女士；非執行董事郭曉濤 先生、付欣女士、蔡方方女士及朱梓陽先生；及獨立非執行董事湯雲為先生、郭 田勇先生及周永健博士組成。 董事會會議通告 平安健康醫療科技有限公司（「本公司」及其附屬公司「本集團」）董事（「董事」）會 （「董事會」）謹此宣佈，董事會會議將於二零二六年三月二十四日（星期二）舉行， 以審議及批准，其中包括，本集團截至二零二五年十二月三十一日止之全年業績 及其發佈以及考慮派發末期股息（如有）之建議。 承董事會命 平安健康醫療科技有限公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 平安健康醫療科技有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01833 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 | USD | | 50,000 | 本月底法定/ ...

Group 1 - Southbound funds increased their holdings in Ping An Good Doctor (01833.HK) by 648,200 shares on February 27 [1] - Over the past 5 trading days, there were 4 days of net increases in holdings by southbound funds, totaling 2,591,800 shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 11,932,400 shares [1] - Currently, southbound funds hold 488 million shares of Ping An Good Doctor, representing 22.53% of the company's total issued ordinary shares [1] Group 2 - Ping An Good Doctor is engaged in providing medical and health services through mobile platforms and offline resources [1] - The company operates through two segments: the medical services segment, which includes online consultations, referrals, appointment scheduling, hospitalization arrangements, disease diagnosis, and sales of related pharmaceuticals and medical devices [1] - The health services segment offers standardized health service packages that integrate various medical health institution services to meet users' health-related needs, covering categories such as physical examinations, elderly care, dental services, anti-aging, and general health [1]

Investment Rating - The investment rating for the company is "Buy" with a current price of 13.34 HKD and a target value of 19.65 HKD [2]. Core Insights - The company is expected to achieve steady revenue growth, with a projected revenue increase of 13.6% in 2025, reaching 5.46 billion RMB. The gross margin is anticipated to remain stable, and the adjusted net profit is expected to grow by 132% to 368 million RMB, with an adjusted net profit margin increasing by 3.4 percentage points to 6.7% [7][9]. - The focus on strategic business areas is expected to drive rapid growth in B-end enterprise health income, while F-end growth remains stable. The collaboration with the group to create a comprehensive health service product is expected to accelerate the expansion of corporate clients [7][9]. - The company is enhancing its service network through the "Ping An Circle," which integrates various health service resources to provide a one-stop health service solution for corporate clients [7][9]. Financial Forecast - Revenue projections for the company are as follows: - 2023A: 4,674 million RMB - 2024A: 4,808 million RMB - 2025E: 5,460 million RMB (growth rate: 13.6%) - 2026E: 6,257 million RMB (growth rate: 14.6%) - 2027E: 7,202 million RMB (growth rate: 15.1%) [6][13]. - The adjusted net profit is forecasted to be: - 2025E: 368 million RMB - 2026E: 489 million RMB - 2027E: 618 million RMB [6][17]. Business Segmentation - Revenue by business segment is projected as follows: - Medical Services: - 2025E: 2,483 million RMB - 2026E: 2,856 million RMB - 2027E: 3,284 million RMB - Health Services: - 2025E: 2,592 million RMB - 2026E: 2,929 million RMB - 2027E: 3,310 million RMB - Elderly Care Services: - 2025E: 385 million RMB - 2026E: 472 million RMB - 2027E: 608 million RMB [13][17]. Valuation and Comparison - The company is valued at a price-to-sales (P/S) ratio of 6 times for 2026, leading to a target price of 19.65 HKD per share. This valuation reflects the company's focus on high-margin services and operational efficiency improvements [7][10]. - Compared to peers like Alibaba Health and JD Health, which have lower gross margins, the company maintains a higher gross margin of approximately 32% [10][18].

Group 1 - Southbound funds increased their holdings in Ping An Good Doctor (01833.HK) by 692,000 shares on February 23 [1] - Over the past 5 trading days, there were 4 days of net increases in holdings by southbound funds, totaling 6.749 million shares [1] - In the last 20 trading days, there were 12 days of net increases, amounting to 5.052 million shares [1] Group 2 - As of now, southbound funds hold 485 million shares of Ping An Good Doctor, representing 22.45% of the company's total issued ordinary shares [1] - Ping An Good Doctor operates through mobile platforms and offline resources to provide medical and health services [1] - The company has two business segments: the medical services segment focuses on online consultations, referrals, appointment scheduling, hospitalization arrangements, disease diagnosis, and related sales of pharmaceuticals and medical devices [1] - The health services segment offers standardized health service packages that integrate various medical health institution services to meet users' health-related needs, covering categories such as physical examinations, elderly care, dental care, anti-aging, and general health services [1]

Group 1 - The mainland internet healthcare sector is entering a new phase driven by tech giants accelerating AI innovation and government policy support, such as the online initial diagnosis pilot program launched in Beijing [1] - Despite challenges in profitability, leading companies are leveraging AI ecosystems and innovative strategies for long-term sustainable growth [1] Group 2 - The company maintains a "Buy" rating for Alibaba Health (00241) with a target price of HKD 7.8, expecting a compound annual growth rate (CAGR) of 13% in revenue and 24% in adjusted net profit from FY2026 to FY2028, driven by growth in innovative drugs and healthcare products, deepening synergy with Alibaba Group (09988), and increasing AI application [1] - The company also favors Ping An Good Doctor (01833) with a "Buy" rating and a target price of HKD 20, anticipating a CAGR of 16% in revenue and 56% in adjusted net profit from FY2025 to FY2027, supported by deepening synergy with Ping An Insurance (02318) and ongoing AI empowerment [1] Group 3 - The company maintains an "Overweight" rating for the mainland healthcare sector, preferring leading innovative pharmaceutical companies and contract research, development, and manufacturing organizations (CRDMOs) [2] - The company is optimistic about internet healthcare firms that effectively utilize real-world data to optimize AI algorithms and enhance service quality [2] - Preferred stocks include BeiGene (06160), Innovent Biologics (01801), Hansoh Pharmaceutical (03692), China Biologic Products (01177), Hutchison China MediTech (00013), WuXi Biologics (02269), WuXi AppTec (02359), and Alibaba Health [2]